US Patent

US11492353 — Methods and compounds for treating Paramyxoviridae virus infections

Composition of Matter · Assigned to Gilead Sciences Inc · Expires 2031-12-08 · 6y remaining

Vulnerability score 1/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects methods and compounds for treating Paramyxoviridae virus infections, particularly Human parainfluenza and Human respiratory syncytial virus infections.

USPTO Abstract

Provided are methods for treating Paramyxoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula I:wherein the 1′ position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Human parainfluenza and Human respiratory syncytial virus infections.

Drugs covered by this patent

Patent Metadata

Patent number
US11492353
Jurisdiction
US
Classification
Composition of Matter
Expires
2031-12-08
Drug substance claim
Yes
Drug product claim
No
Assignee
Gilead Sciences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.